Investor Relations R&D Day

Newron Pharmaceuticals SpA: Expanded Global and U.S. Investor Visibility

  • Newron is a Swiss-traded biopharmaceutical company focused on late-stage clinical therapies for patients with diseases of the central nervous system.
  • Newron was looking to provide investors a further understanding of their investment thesis, build their visibility globally, and in particular, expand their presence within the US investment, sell-side analyst and investment banking community.
  • Execute a globally viewed scientific and investor-oriented R&D Day to increase investor visibility.
  • Develop a U.S.-centric marketing strategy for the event, including message and presentation development, event and location branding and broadcast design.
  • Audience acquisition through extensive media relations, press release distribution, focused email campaigns and personal investor outreach.
  • Secured the participation of two of the world’s leading KOLs in Rett syndrome and Schizophrenia as speakers.
  • More than 850 webcast participants from 7 countries worldwide.
  • 35 in-person attendees, including representatives from 8 investment banks and 9 sell-side analysts.
  • Extensive media coverage including video of KOL Daniel Glaze, MD, of Baylor College of Medicine discussing the state of Rett syndrome treatment.